Clearly identifying challenges and opportunities early
Transplantation significantly improves a recipient’s quality of life and potentially extends their life expectancy by decades. Although clinical outcomes have improved steadily, transplant rejection and immunosuppression minimization remain key challenges to improving long-term graft survival and health.
Detecting transplant rejection early is a challenge and an opportunity. Immunological rejection is the leading cause of graft failure; “silent” subclinical acute rejection is a key component of this problem. The earlier rejection can be detected, the earlier rejection can be addressed – and the cumulative effect of multiple rejection episodes can be minimized.
Post-transplantation, recipients are prescribed lifelong immunosuppressive antirejection medications. These medications have significant adverse effects – so maintaining optimal levels of medication means striking the balance between effective immunosuppression and minimizing risk of complications.
Eurofins’ suite of non-invasive biomarker tests reliably detects the full range of rejection and confirms immune quiescence. Biomarker-based diagnostic guidance can reliably inform clinical decision-making, leading to better patient experience and improved long-term graft outcomes.
